tiprankstipranks
Shanghai Pharmaceuticals Holding Co Ltd Class H (HK:2607)
HKEX:2607
Holding HK:2607?
Track your performance easily

Shanghai Pharmaceuticals Holding Co (2607) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

2607 Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Shanghai
Pharmaceuticals Holding Co
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2607 Stock 12 Month Forecast

There Are No Analyst Ratings for HK:2607 In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

2607 Financial Forecast

2607 Earnings Forecast

Next quarter’s earnings estimate for 2607 is HK$0.24 with a range of HK$0.22 to HK$0.28. The previous quarter’s EPS was HK$0.32. 2607 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.47% of the time in the same period. In the last calendar year 2607 has Outperformed its overall industry.
Next quarter’s earnings estimate for 2607 is HK$0.24 with a range of HK$0.22 to HK$0.28. The previous quarter’s EPS was HK$0.32. 2607 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.47% of the time in the same period. In the last calendar year 2607 has Outperformed its overall industry.

2607 Sales Forecast

Next quarter’s sales forecast for 2607 is HK$76.02B with a range of HK$75.27B to HK$76.77B. The previous quarter’s sales results were HK$76.19B. 2607 beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 51.03% of the time in the same period. In the last calendar year 2607 has Outperformed its overall industry.
Next quarter’s sales forecast for 2607 is HK$76.02B with a range of HK$75.27B to HK$76.77B. The previous quarter’s sales results were HK$76.19B. 2607 beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 51.03% of the time in the same period. In the last calendar year 2607 has Outperformed its overall industry.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley
HK$17HK$17.5
Buy
38.23%
Upside
Reiterated
06/06/24
Shanghai Pharmaceuticals Holdings (2607:HK) (FJLLF) PT Raised to HK$17.50 at Morgan StanleyMorgan Stanley analyst Laurence Tam raised the price target on Shanghai Pharmaceuticals Holdings (2607:HK) (OTC: FJLLF) to HK$17.50 (from HK$17.00) while maintaining a Overweight rating.
Goldman Sachs
HK$13.98HK$13.44
Sell
6.16%
Upside
Reiterated
04/03/24
Shanghai Pharmaceuticals Holdings (2607:HK) (FJLLF) PT Lowered to HK$13.44 at Goldman SachsGoldman Sachs analyst Ziyi Chen lowered the price target on Shanghai Pharmaceuticals Holdings (2607:HK) (OTC: FJLLF) to HK$13.44 (from HK$13.98) while maintaining a Sell rating.
CLSA Analyst forecast on HK:2607
Unknown Analyst
Not Ranked
CLSA
HK$15.5HK$13.54
Buy
6.95%
Upside
Reiterated
03/31/24
Shanghai Pharmaceuticals Holdings (2607:HK) (FJLLF) PT Lowered to HK$13.54 at CLSACLSA analyst John Yung lowered the price target on Shanghai Pharmaceuticals Holdings (2607:HK) (OTC: FJLLF) to HK$13.54 (from HK$15.50) while maintaining a Buy (1) rating.

Best Analysts Covering Shanghai Pharmaceuticals Holding Co

Which Analyst Should I Follow If I Want to Buy HK:2607 and Sell After:
1 Month
xxx
Success Rate
2/2 ratings generated profit
100%
Average Return
+5.15%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +5.15% per trade.
3 Months
xxx
Success Rate
1/2 ratings generated profit
50%
Average Return
-0.55%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -0.55% per trade.
1 Year
Laurence TamMorgan Stanley
Success Rate
2/2 ratings generated profit
100%
Average Return
+29.00%
reiterated a buy rating 6 months ago
Copying Laurence Tam's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +29.00% per trade.
2 Years
xxx
Success Rate
2/2 ratings generated profit
100%
Average Return
+29.00%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +29.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2607 Analyst Recommendation Trends

Rating
Oct 23
Nov 23
Dec 23
Apr 24
Jun 24
Strong Buy
0
1
2
2
2
Buy
0
0
0
0
0
Hold
1
1
0
0
0
Sell
1
1
1
1
1
Strong Sell
0
0
0
0
0
total
2
3
3
3
3
In the current month, 2607 has received 2 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. 2607 average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

2607 Stock Forecast FAQ

What is HK:2607’s average 12-month price target, according to analysts?
Currently, no data Available
What is HK:2607’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for HK:2607, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Shanghai Pharmaceuticals Holding Co Ltd Class H a Buy, Sell or Hold?
      Currently, no data Available
      What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s share price target?
      Currently, no data Available
      What do analysts say about Shanghai Pharmaceuticals Holding Co Ltd Class H?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Shanghai Pharmaceuticals Holding Co Ltd Class H?
      To buy shares of HK:2607, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis